glp 1 drugs and parkinson's disease Glucagon-like peptide-1 medicines in neurological psychiatric disorders: Cell Reports Medicine parkinson's disease triple agonist glp-1
Description
Types of GLP-1 Six agents are available in the EU market but only 3 have reached the Egyptian market (Exenatide, Liraglutide and Dulaglutide)
In the intensely competitive GLP-1 drug market, simply enhancing drug efficacy is no longer sufficient to make new products stand out
One critical warning
Mattison McGee This is genuinely a miracle drug
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
